Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0LJ0L
|
||||
| Former ID |
DIB015250
|
||||
| Drug Name |
Lu-AA47070
|
||||
| Synonyms |
Adenosine A2a antagonists (Parkinson's disease), Lundbeck
|
||||
| Indication | Parkinson's disease [ICD9: 332; ICD10:G20] | Discontinued in Phase 1 | [1] | ||
| Company |
H. Lundbeck A/S
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
P(=O)(OCn1/c(=N/C(=O)c2cc(c(c(c2)F)NC(=O)CC(C)(C)C)F)/s<br />cc1)(O)O
|
||||
| Target and Pathway | |||||
| Target(s) | Adenosine A2a receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| Calcium signaling pathway | |||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Vascular smooth muscle contraction | |||||
| Parkinson's disease | |||||
| Alcoholism | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| PathWhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | ||||
| Reactome | NGF-independant TRKA activation | ||||
| Adenosine P1 receptors | |||||
| G alpha (s) signalling events | |||||
| Surfactant metabolism | |||||
| WikiPathways | Nucleotide GPCRs | ||||
| Monoamine Transport | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| NGF signalling via TRKA from the plasma membrane | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, Other | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027391) | ||||
| REF 2 | The novel adenosine A2A antagonist Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade. Pharmacol Biochem Behav. 2012 Jan;100(3):498-505. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.